Non-Invasive Vagal Nerve Stimulation in Patients with Opioid Use Disorders

阿片类药物使用障碍患者的无创迷走神经刺激

基本信息

  • 批准号:
    10718694
  • 负责人:
  • 金额:
    $ 195.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-15 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

Treatment of Opioid Use Disorders (OUDs) includes medications with effects on opioid receptors such as buprenorphine, but access is limited for many patients and others are opposed to treating addictions with medications that have opioid agonist properties. Naltrexone is an opioid antagonist that is more acceptable for many patients, and recent studies show it to be equivalent in efficacy. Initiation of treatment with long-acting naltrexone, however, requires a period of abstinence of about seven days during which time patients suffer from intense symptoms of withdrawal with a risk of relapse that can lead to overdose-related death. Opioids have an inhibitory effect on norepinephrine and the sympathetic nervous system, and many symptoms of withdrawal are driven by rebound activation of these systems. Dopaminergic systems in brain areas including ventral striatum (nucleus accumbens) and medial prefrontal cortex (anterior cingulate) play an important role in opioid addiction, craving and relapse, as do increases in inflammation. This project will assess a form of neuromodulation involving non-invasive electrical stimulation of the vagus nerve that may play a useful role during the period of opioid withdrawal before the initiation of long-term naltrexone treatment in blocking norepinephrine, sympathetic, and inflammatory responses and enhancing peripheral parasympathetic and central brain function in areas modulating drug craving (ventral striatum, anterior cingulate). Our preliminary data on the effects of non-invasive Vagal Nerve Stimulation (nVNS) on stress response in traumatized human subjects and patients with posttraumatic stress disorder (PTSD) show that nVNS reliably blocks peripheral sympathetic and enhances parasympathetic function, reduces inflammatory responses (interleukin-6, or IL-6), and enhances central brain responses (anterior cingulate) to stress. We now propose to apply this technology to the treatment of patients with OUDs. Following verification using modelling and determination of optimal dosing parameters, we will use these parameters to assess effects of nVNS versus sham stimulation on opioid craving, peripheral autonomic, cardiovascular, inflammatory, and brain functional responses measured with High-Resolution Positron Emission Tomography (HR-PET) and radiolabeled water to videos of drug cues in recently treated patients with OUDs. Based on the outcome of this research, we will proceed to the UH3 phase, which will involve a randomized, sham-controlled trial of nVNS in patients with OUDs during the one to two week period of opioid withdrawal followed by assessment of craving, HR-PET imaging of both brain function and brain dopaminergic function, and assessment of peripheral autonomic, cardiovascular and inflammatory responses in conjunction with administration of nVNS or sham. We hypothesize that nVNS will reduce opioid craving and inflammatory, peripheral autonomic and cardiovascular responses and enhance brain responses (anterior cingulate function and dopamine function in ventral striatum), and promote successful conversion to long-acting naltrexone, in patients with OUDs.
阿片使用障碍(OUDs)的治疗包括对阿片受体有作用的药物,如

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Douglas Bremner其他文献

James Douglas Bremner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Douglas Bremner', 18)}}的其他基金

Transcutaneous Vagal Nerve Stimulation in Veterans with Posttraumatic Stress Disorder
患有创伤后应激障碍的退伍军人的经皮迷走神经刺激
  • 批准号:
    10478766
  • 财政年份:
    2022
  • 资助金额:
    $ 195.21万
  • 项目类别:
Non-Invasive Vagal Nerve Stimulation in Veterans with Mild Traumatic Brain Injury (mTBI)
对患有轻度创伤性脑损伤 (mTBI) 的退伍军人进行无创迷走神经刺激
  • 批准号:
    10311521
  • 财政年份:
    2020
  • 资助金额:
    $ 195.21万
  • 项目类别:
Dopamine function, inflammation and connectivity in PTSD
PTSD 中的多巴胺功能、炎症和连接
  • 批准号:
    10405521
  • 财政年份:
    2020
  • 资助金额:
    $ 195.21万
  • 项目类别:
Non-Invasive Vagal Nerve Stimulation in Patients with Opioid Use Disorders
阿片类药物使用障碍患者的无创迷走神经刺激
  • 批准号:
    10402169
  • 财政年份:
    2020
  • 资助金额:
    $ 195.21万
  • 项目类别:
Dopamine function, inflammation and connectivity in PTSD
PTSD 中的多巴胺功能、炎症和连接
  • 批准号:
    9973958
  • 财政年份:
    2020
  • 资助金额:
    $ 195.21万
  • 项目类别:
Non-Invasive Vagal Nerve Stimulation in Veterans with Mild Traumatic Brain Injury (mTBI)
对患有轻度创伤性脑损伤 (mTBI) 的退伍军人进行无创迷走神经刺激
  • 批准号:
    10543080
  • 财政年份:
    2020
  • 资助金额:
    $ 195.21万
  • 项目类别:
Dopamine function, inflammation and connectivity in PTSD
PTSD 中的多巴胺功能、炎症和连接
  • 批准号:
    10657425
  • 财政年份:
    2020
  • 资助金额:
    $ 195.21万
  • 项目类别:
Non invasive vagal nerve stimulation in opioid use disorders
阿片类药物使用障碍中的无创迷走神经刺激
  • 批准号:
    10376890
  • 财政年份:
    2020
  • 资助金额:
    $ 195.21万
  • 项目类别:
A Multisite Randomized Controlled Trial of Mindfulness Meditation Therapy for PTS
正念冥想疗法治疗 PTS 的多中心随机对照试验
  • 批准号:
    8453248
  • 财政年份:
    2012
  • 资助金额:
    $ 195.21万
  • 项目类别:
A Multisite Randomized Controlled Trial of Mindfulness Meditation Therapy for PTS
正念冥想疗法治疗 PTS 的多中心随机对照试验
  • 批准号:
    8264703
  • 财政年份:
    2012
  • 资助金额:
    $ 195.21万
  • 项目类别:

相似海外基金

NEM-EMERGE: An integrated set of novel approaches to counter the emergence and proliferation of invasive and virulent soil-borne nematodes
NEM-EMERGE:一套综合的新方法来对抗入侵性和剧毒土传线虫的出现和扩散
  • 批准号:
    10080598
  • 财政年份:
    2024
  • 资助金额:
    $ 195.21万
  • 项目类别:
    EU-Funded
Non invasive methods to accelerate the development of injectable therapeutic depots
非侵入性方法加速注射治疗储库的开发
  • 批准号:
    EP/Z532976/1
  • 财政年份:
    2024
  • 资助金额:
    $ 195.21万
  • 项目类别:
    Research Grant
CAREER: Branched Amphiphilic Peptide Capsules (BAPCs) for the delivery of lethal dsRNA into invasive organisms
事业:分支两亲肽胶囊 (BAPC) 用于将致命的 dsRNA 传递到入侵生物体中
  • 批准号:
    2340070
  • 财政年份:
    2024
  • 资助金额:
    $ 195.21万
  • 项目类别:
    Continuing Grant
SBIR Phase II: A mesh-free, sling-free, minimally invasive treatment for stress urinary incontinence in women
SBIR II 期:无网、无吊带的微创治疗女性压力性尿失禁
  • 批准号:
    2233106
  • 财政年份:
    2024
  • 资助金额:
    $ 195.21万
  • 项目类别:
    Cooperative Agreement
SUPer-REsolution non-invasive Muscle measurements with miniaturised magnetIc SEnsors (SUPREMISE)
使用微型磁性传感器 (SUPREMISE) 进行超分辨率非侵入性肌肉测量
  • 批准号:
    EP/X031950/1
  • 财政年份:
    2024
  • 资助金额:
    $ 195.21万
  • 项目类别:
    Fellowship
I-Corps: Non-Invasive Software Tool for Risk Assessment of Intracranial Aneurysms (IA)
I-Corps:用于颅内动脉瘤 (IA) 风险评估的非侵入性软件工具
  • 批准号:
    2402381
  • 财政年份:
    2024
  • 资助金额:
    $ 195.21万
  • 项目类别:
    Standard Grant
Creating a non-invasive window into the mind
创建一个非侵入性的心灵窗口
  • 批准号:
    DP240102254
  • 财政年份:
    2024
  • 资助金额:
    $ 195.21万
  • 项目类别:
    Discovery Projects
I-Corps: Translation Potential of a Minimally Invasive Continuum Surgical Robot for the Eye/Ear
I-Corps:眼/耳微创连续手术机器人的翻译潜力
  • 批准号:
    2420989
  • 财政年份:
    2024
  • 资助金额:
    $ 195.21万
  • 项目类别:
    Standard Grant
I-Corps: Translation potential of minimally invasive tubular retractors to maximize visualization in spine operations
I-Corps:微创管状牵开器的翻译潜力,可最大限度地提高脊柱手术的可视化
  • 批准号:
    2422243
  • 财政年份:
    2024
  • 资助金额:
    $ 195.21万
  • 项目类别:
    Standard Grant
SBIR Phase I: Novel Camera-Projector Device Leveraging Markerless Skin Registration and Projected Augmented Reality Software to Enable Navigation for Minimally Invasive Procedures
SBIR 第一阶段:新型相机投影仪设备利用无标记皮肤配准和投影增强现实软件实现微创手术导航
  • 批准号:
    2321906
  • 财政年份:
    2024
  • 资助金额:
    $ 195.21万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了